$ATIP
ATI Physical Therapy, Inc.

2023 Q3 Form 10-Q Financial Statement

#000181584923000009 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $177.5M $172.3M $163.3M
YoY Change 13.18% 5.54% -0.45%
Cost Of Revenue $149.8M $145.8M $140.0M
YoY Change 5.69% 4.11% -43.76%
Gross Profit $27.67M $26.57M $23.28M
YoY Change 83.64% 14.14% -63.71%
Gross Profit Margin 15.59% 15.42% 14.26%
Selling, General & Admin $25.09M $36.57M $32.06M
YoY Change -0.7% 14.06% 21.5%
% of Gross Profit 90.67% 137.63% 137.72%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.115M $9.165M $10.26M
YoY Change -8.15% -10.66% 13.32%
% of Gross Profit 32.95% 34.49% 44.06%
Operating Expenses $25.09M $36.57M $35.31M
YoY Change -0.7% 3.57% 33.81%
Operating Profit -$764.0K -$12.36M -$12.03M
YoY Change -99.36% 2.73% -97.29%
Interest Expense -$15.48M -$16.68M -$11.38M
YoY Change 31.39% 46.6% -72.78%
% of Operating Profit
Other Income/Expense, Net -$117.0K -$618.0K $2.475M
YoY Change -40.0% -124.97% -143.99%
Pretax Income -$14.48M -$21.66M -$148.8M
YoY Change -88.31% -85.44% -69.47%
Income Tax $100.0K $100.0K -$13.03M
% Of Pretax Income
Net Earnings -$15.20M -$22.71M -$135.5M
YoY Change -86.93% -83.25% -68.87%
Net Earnings / Revenue -8.56% -13.17% -83.01%
Basic Earnings Per Share -$4.42 -$17.74 -$34.49
Diluted Earnings Per Share -$4.42 -$17.74 -$664.9K
COMMON SHARES
Basic Shares Outstanding 4.206M shares 208.5M shares 206.8M shares
Diluted Shares Outstanding 4.154M shares 4.122M shares 4.077M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.70M $37.70M $79.68M
YoY Change -59.44% -52.69% -12.02%
Cash & Equivalents $19.73M $37.68M $79.68M
Short-Term Investments
Other Short-Term Assets $6.367M $6.225M $27.68M
YoY Change -53.75% -77.51% 267.01%
Inventory
Prepaid Expenses $12.46M $14.30M
Receivables $84.97M $80.78M $83.19M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $123.5M $139.0M $190.5M
YoY Change -21.39% -27.06% 2.61%
LONG-TERM ASSETS
Property, Plant & Equipment $109.7M $114.8M $380.8M
YoY Change -15.5% -69.85% 184.22%
Goodwill $289.7M $289.7M
YoY Change -14.31%
Intangibles $246.0M $246.2M
YoY Change -15.68%
Long-Term Investments
YoY Change
Other Assets $1.866M $1.862M $2.013M
YoY Change -9.77% -7.5% 7.59%
Total Long-Term Assets $855.0M $871.3M $1.119B
YoY Change -14.51% -22.14% -41.55%
TOTAL ASSETS
Total Short-Term Assets $123.5M $139.0M $190.5M
Total Long-Term Assets $855.0M $871.3M $1.119B
Total Assets $978.5M $1.010B $1.310B
YoY Change -15.44% -22.86% -37.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.46M $12.54M $14.37M
YoY Change 3.22% -12.76% 17.25%
Accrued Expenses $108.0M $109.1M $109.9M
YoY Change 11.3% -0.77% 8.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $119.4M $126.5M $131.9M
YoY Change 2.97% -4.1% 2.31%
LONG-TERM LIABILITIES
Long-Term Debt $512.8M $512.0M $478.5M
YoY Change 6.85% 7.0% -12.48%
Other Long-Term Liabilities $1.654M $1.644M $260.8M
YoY Change -14.92% -99.37% 3363.03%
Total Long-Term Liabilities $1.654M $1.644M $739.3M
YoY Change -99.66% -99.78% 33.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $119.4M $126.5M $131.9M
Total Long-Term Liabilities $1.654M $1.644M $739.3M
Total Liabilities $851.2M $869.6M $908.1M
YoY Change -1.54% -4.24% -28.19%
SHAREHOLDERS EQUITY
Retained Earnings -$1.404B -$1.388B
YoY Change 13.5%
Common Stock $0.00 $0.00
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$94.18M -$78.08M $401.5M
YoY Change
Total Liabilities & Shareholders Equity $978.5M $1.010B $1.310B
YoY Change -15.44% -22.86% -37.64%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$15.20M -$22.71M -$135.5M
YoY Change -86.93% -83.25% -68.87%
Depreciation, Depletion And Amortization $9.115M $9.165M $10.26M
YoY Change -8.15% -10.66% 13.32%
Cash From Operating Activities -$12.45M $8.905M -$6.006M
YoY Change -52.72% -248.27% -76.84%
INVESTING ACTIVITIES
Capital Expenditures $4.602M $4.556M -$9.069M
YoY Change -208.28% -150.24% -52.79%
Acquisitions
YoY Change
Other Investing Activities $96.00K -$490.0K $109.0K
YoY Change 1500.0% -549.54% -54.6%
Cash From Investing Activities -$4.506M -$5.046M -$8.960M
YoY Change 6.17% -43.68% -52.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -978.0K -29.26M -151.0K
YoY Change 86.64% 19274.17% -97.26%
NET CHANGE
Cash From Operating Activities -12.45M 8.905M -6.006M
Cash From Investing Activities -4.506M -5.046M -8.960M
Cash From Financing Activities -978.0K -29.26M -151.0K
Net Change In Cash -17.94M -25.40M -15.12M
YoY Change -42.34% 68.0% -70.01%
FREE CASH FLOW
Cash From Operating Activities -$12.45M $8.905M -$6.006M
Capital Expenditures $4.602M $4.556M -$9.069M
Free Cash Flow -$17.06M $4.349M $3.063M
YoY Change -22.79% 41.98% -145.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payment For Contingent Consideration Liability Investing Activities
PaymentForContingentConsiderationLiabilityInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17618000 usd
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
200000 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
200000 shares
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
792000 usd
CY2022Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1496000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1501000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
25830000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73110000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-280284000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-280284000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4077000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4110000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4110000 shares
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
511507000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
19725000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
22000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1960000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
3752000 usd
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
473000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-473000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-137750000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
12000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1959000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
2708000 usd
CY2022Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
139000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-177000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-135546000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
267019000 usd
us-gaap Profit Loss
ProfitLoss
-46959000 usd
us-gaap Profit Loss
ProfitLoss
-273946000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
283561000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19041000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20369000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6485000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8611000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
151000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-36314000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
23836000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
24071000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4208000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3919000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1554000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1407000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
4318000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-444000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2809000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-793000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
163000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
7010000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2861000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1501000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
25830000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6105000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9349000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7555000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-22000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1850000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
10803000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-23427000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
45000 usd
ati Increase Decrease In Medicare Accelerated And Advance Payment Funds
IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds
0 usd
ati Increase Decrease In Medicare Accelerated And Advance Payment Funds
IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds
-10759000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5319000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32737000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9990000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17841000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
146000 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
355000 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
77000 usd
us-gaap Payment For Contingent Consideration Liability Investing Activities
PaymentForContingentConsiderationLiabilityInvestingActivities
490000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10125000 usd
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 usd
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
500000000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3243000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Payments Of Debt Restructuring Costs
PaymentsOfDebtRestructuringCosts
6287000 usd
us-gaap Payments Of Debt Restructuring Costs
PaymentsOfDebtRestructuringCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
84000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
12952000 usd
ati Payment Of Debt Issuance Discount
PaymentOfDebtIssuanceDiscount
0 usd
ati Payment Of Debt Issuance Discount
PaymentOfDebtIssuanceDiscount
10000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
555048000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
144667000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
20333000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
24750000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 usd
ati Payment Of Stock Issuance Costs And Issuance Discounts
PaymentOfStockIssuanceCostsAndIssuanceDiscounts
0 usd
ati Payment Of Stock Issuance Costs And Issuance Discounts
PaymentOfStockIssuanceCostsAndIssuanceDiscounts
4935000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
397000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
66000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
34000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
1675000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
612000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30016000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
81419000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45460000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31064000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83139000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48616000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37679000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79680000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-4306000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
6460000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1495000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1550000 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
100000000 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 usd
ati Debt Discount Incurred During Noncash Or Partial Noncash Transaction
DebtDiscountIncurredDuringNoncashOrPartialNoncashTransaction
1797000 usd
ati Debt Discount Incurred During Noncash Or Partial Noncash Transaction
DebtDiscountIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
ati Capital Contribution From Recognition Of Delayed Draw Right Asset
CapitalContributionFromRecognitionOfDelayedDrawRightAsset
690000 usd
ati Capital Contribution From Recognition Of Delayed Draw Right Asset
CapitalContributionFromRecognitionOfDelayedDrawRightAsset
0 usd
ati Preferred Stock Dividends And Redemption Value Adjustments
PreferredStockDividendsAndRedemptionValueAdjustments
73584000 usd
ati Preferred Stock Dividends And Redemption Value Adjustments
PreferredStockDividendsAndRedemptionValueAdjustments
0 usd
us-gaap Interest Paid Net
InterestPaidNet
24698000 usd
us-gaap Interest Paid Net
InterestPaidNet
17822000 usd
us-gaap Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
5135000 usd
us-gaap Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
55000 usd
us-gaap Nature Of Operations
NatureOfOperations
Overview of the Company<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATI Physical Therapy, Inc., together with its subsidiaries (herein referred to as “we,” "our," “the Company,” “ATI Physical Therapy” and “ATI”), is a nationally recognized healthcare company, specializing in outpatient rehabilitation and adjacent healthcare services. The Company provides outpatient physical therapy services under the name ATI Physical Therapy and, as of June 30, 2023, had 911 clinics located in 24 states (as well as 18 clinics under management service agreements). The Company offers a variety of services within its clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services. The Company’s direct and indirect wholly-owned subsidiaries include, but are not limited to, Wilco Holdco, Inc., ATI Holdings Acquisition, Inc. and ATI Holdings, LLC.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 and CARES Act</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic in the United States resulted in changes to our operating environment. Although the direct impact on our business has decreased since the peak impact in 2020, we continue to closely monitor the remaining impacts from the pandemic including its direct or indirect effects on macroeconomic factors, the labor markets in which we operate, and the physical therapy and broader healthcare landscape. Throughout the duration of the pandemic and declared public health emergency, and continuing hereafter, our priorities have been protecting the health and safety of employees and patients, maximizing the availability of services to satisfy patient needs and improving the operational and financial stability of our business. While we expect the disruption caused by COVID-19 and resulting impacts to diminish over time, we cannot predict the length of such impacts, and if such impacts continue for an extended period, it could have a continued effect on the Company’s results of operations, financial condition and cash flows, which could be material.</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law providing reimbursement, grants, waivers and other funds to assist health care providers during the COVID-19 pandemic. The Company realized benefits under the CARES Act including, but not limited to, the receipt of Medicare Accelerated and Advance Payment Program ("MAAPP") funds and deferral of depositing the employer portion of Social Security taxes, interest-free and penalty-free. During the year ended December 31, 2022, the remaining obligations related to these benefits were applied and repaid. During the six months ended June 30, 2022, the Company applied $10.7 million in MAAPP funds against the outstanding liability at that time.</span></div>
CY2023Q2 us-gaap Number Of Stores
NumberOfStores
911 clinic
CY2023Q2 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
24 state
CY2023Q2 ati Number Of Stores Under Management Service Agreements
NumberOfStoresUnderManagementServiceAgreements
18 clinic
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5300000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23700000 usd
us-gaap Profit Loss
ProfitLoss
-47000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The effect of any change in estimates will be recognized in the current period of the change.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
800000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
172337000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
163293000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
339269000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
317115000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
286458000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Transfers
GoodwillTransfers
3192000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
289650000 usd
CY2022Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
1045700000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
246213000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
246582000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
204200000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
360961000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
352896000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
246174000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
229206000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114787000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
123690000 usd
CY2023Q2 us-gaap Health Care Organization Accounts Payable To Third Party Payor
HealthCareOrganizationAccountsPayableToThirdPartyPayor
7255000 usd
CY2022Q4 us-gaap Health Care Organization Accounts Payable To Third Party Payor
HealthCareOrganizationAccountsPayableToThirdPartyPayor
6117000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6162000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5551000 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
6116000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
762000 usd
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
4716000 usd
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0 usd
CY2023Q2 ati Accrued Occupancy Costs Current
AccruedOccupancyCostsCurrent
1985000 usd
CY2022Q4 ati Accrued Occupancy Costs Current
AccruedOccupancyCostsCurrent
2410000 usd
CY2023Q2 ati Accrued Contract Labor Current
AccruedContractLaborCurrent
1921000 usd
CY2022Q4 ati Accrued Contract Labor Current
AccruedContractLaborCurrent
4483000 usd
CY2023Q2 ati Debt Instrument Delayed Draw Right Assets
DebtInstrumentDelayedDrawRightAssets
3500000 usd
CY2022Q1 ati Proceeds From Issuance Of Temporary Equity And Warrants
ProceedsFromIssuanceOfTemporaryEquityAndWarrants
165000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
23450000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
511042000 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
534492000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
16181000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2800000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4200000 usd
CY2022Q1 ati Proceeds From Issuance Of Temporary Equity And Warrants
ProceedsFromIssuanceOfTemporaryEquityAndWarrants
165000000 usd
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
200000 shares
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
200000 shares
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
200000 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
200000 shares
CY2022Q1 ati Proceeds From Issuance Of Temporary Equity And Warrants
ProceedsFromIssuanceOfTemporaryEquityAndWarrants
165000000 usd
CY2023Q2 ati Temporary Equity Stated Value Per Share
TemporaryEquityStatedValuePerShare
1175.08
CY2022Q4 ati Temporary Equity Stated Value Per Share
TemporaryEquityStatedValuePerShare
1108.34
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
140340000 usd
ati Temporary Equity Write Off Original Issue Discount
TemporaryEquityWriteOffOriginalIssueDiscount
1447000 usd
ati Temporary Equity Write Off Issuance Costs
TemporaryEquityWriteOffIssuanceCosts
2880000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000 usd
ati Temporary Equity Deemed Dividend From Discount On Initial Gross Proceeds Allocation
TemporaryEquityDeemedDividendFromDiscountOnInitialGrossProceedsAllocation
20333000 usd
ati Temporary Equity Pain In Kind Dividends Recognized To Carrying Value
TemporaryEquityPainInKindDividendsRecognizedToCarryingValue
28888000 usd
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
20036000 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
213924000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
20333000 usd
CY2022Q1 ati Class Of Warrant Or Right Unamortized Discount
ClassOfWarrantOrRightUnamortizedDiscount
203000 usd
CY2022Q1 ati Class Of Warrant Or Right Issuance Cost
ClassOfWarrantOrRightIssuanceCost
405000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
19725000 usd
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10280000 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
4369 shares
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5909 shares
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
200000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
575.00
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
575.00
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-99000 usd
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
3357000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
798000 usd
CY2023Q2 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
1648000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
3681000 usd
CY2022Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-71000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
2642000 usd
CY2022Q2 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-66000 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.004
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 usd
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.088
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13000000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.117
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-36300000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-36300000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
16674000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
16784000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
33363000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
33487000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
5468000 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
5331000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
10830000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
10536000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
22142000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
22115000 usd
us-gaap Lease Cost
LeaseCost
44193000 usd
us-gaap Lease Cost
LeaseCost
44023000 usd
ati Lease Modification Operation Lease Liabilities Additions
LeaseModificationOperationLeaseLiabilitiesAdditions
8800000 usd
ati Lease Modification Operating Lease Assets Additions
LeaseModificationOperatingLeaseAssetsAdditions
8800000 usd
ati Lease Modification Operation Lease Liabilities Additions
LeaseModificationOperationLeaseLiabilitiesAdditions
7500000 usd
ati Lease Modification Operating Lease Assets Additions
LeaseModificationOperatingLeaseAssetsAdditions
7500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
31110000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
32893000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6831000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6900000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
7.2
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
6.9
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
34311000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66189000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
56311000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
49463000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
38178000 usd
CY2023Q2 ati Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
77069000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
321521000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
60303000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
261218000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52194000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
209024000 usd
CY2023Q2 us-gaap Contractual Obligation
ContractualObligation
13800000 usd
CY2022Q4 ati Loss Contingency Number Of Plaintiffs Who Filed Consolidated Amended Complaint
LossContingencyNumberOfPlaintiffsWhoFiledConsolidatedAmendedComplaint
4 segment
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-21749000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-135723000 usd
us-gaap Profit Loss
ProfitLoss
-46959000 usd
us-gaap Profit Loss
ProfitLoss
-273946000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
956000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-177000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2016000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-650000 usd
CY2023Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
44696000 usd
CY2022Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 usd
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
44696000 usd
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 usd
CY2023Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
5709000 usd
CY2022Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
5063000 usd
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
11012000 usd
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
6988000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-73110000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73110000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-140609000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-140609000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-104683000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-104683000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-280284000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-280284000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4122000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4122000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4077000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4077000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4110000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4110000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4038000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4038000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.74
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-34.49
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-34.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-69.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-69.41
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9440000 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
545000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9440000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
545000 shares
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001815849-23-000009-index-headers.html Edgar Link pending
0001815849-23-000009-index.html Edgar Link pending
0001815849-23-000009.txt Edgar Link pending
0001815849-23-000009-xbrl.zip Edgar Link pending
ati-20230630.htm Edgar Link pending
ati-20230630.xsd Edgar Link pending
ati-20230630_g1.jpg Edgar Link pending
ati-20230630_g2.jpg Edgar Link pending
ati-20230630_g3.jpg Edgar Link pending
exhibit311_q22023.htm Edgar Link pending
exhibit312_q22023.htm Edgar Link pending
exhibit32_q22023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
ati-20230630_lab.xml Edgar Link unprocessable
ati-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ati-20230630_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ati-20230630_cal.xml Edgar Link unprocessable
ati-20230630_def.xml Edgar Link unprocessable